Tumor Neoantigens: When Too Much of a Good Thing Is Bad

Anne Trinh; Kornelia Polyak

doi:10.1016/j.ccell.2019.10.009

Tumor Neoantigens: When Too Much of a Good Thing Is Bad

Cancer Cell. 2019 Nov 11;36(5):466-467. doi: 10.1016/j.ccell.2019.10.009.

Authors

Anne Trinh¹, Kornelia Polyak²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: [email protected].

PMID: 31715129
DOI: 10.1016/j.ccell.2019.10.009

Abstract

Immunotherapy has been the most effective in tumors with high mutational burden. However, a recent study in Cell by Wolf et al. demonstrates that high intratumor heterogeneity (ITH) for cancer neoantigens paradoxically attenuates anti-tumor immune responses, suggesting a need to quantify ITH to improve patient selection for checkpoint blockade therapy.

Publication types

Comment

MeSH terms

Antigens, Neoplasm
Humans
Immunotherapy
Melanoma*
Mutation
Programmed Cell Death 1 Receptor / genetics

Substances

Antigens, Neoplasm
Programmed Cell Death 1 Receptor